The use of artificial intelligence and machine learning methods in first trimester pre-eclampsia screening: a systematic review

3	protocol	
4		
6 7	Paula L. Hedley ^{1,2} , Christian M. Hagen ¹ ,Casper Wilstrup ^{1,3} , Michael Christiansen ^{1,4} *	
8 9 10 11 12	 Department for Congenital Disorders, Statens Serum Institut, Copenhagen, 2300 Denmark Brazen Bio, Los Angeles, California, USA Abzu, Copenhagen, 2200, Denmark Department of Biomedical Science, University of Copenhagen, 2200 Copenhagen, Denmark 	
13		
14		
15 16	Email: Paula L. Hedley - <u>phy@ssi.dk</u> ; Christian M. Hagen – <u>unc@ssi.dk</u> ; Casper Wilstrup - <u>casper.wilstrup@abzu.ai</u> ; Michael Christiansen - <u>mic@ssi.dk</u>	
17 18 19 20		
21 22	Short title: An assessment of AI/ML methods in first trimester pre-eclampsia risk prediction: A systematic review protocol	
23		
24		
25		
26		
27		
28		
29 30		
31	* Corresponding author	
32	E-mail: <u>mic@ssi.dk</u> (MC)	

33 Abstract

34 Introduction: Pre-eclampsia (PE) is a leading cause of perinatal morbidity and mortality worldwide. Lowdose aspirin can prevent PE in high risk pregnancies if started early. However, despite intense research into 35 36 the area, first-trimester screening for PE risk is still not a routine part of pregnancy care. Several studies 37 have described the application of artificial intelligence (AI) and machine learning (ML) in risk prediction of 38 PE and its subtypes. A systematic review of available literature is necessary to catalogue the current 39 applications of AI/ML methods in early pregnancy screening for PE, in order to better inform the 40 development of clinically relevant risk prediction algorithms which will enable timely intervention and the 41 development of new treatment strategies. The aim of this systematic review is to identify and assess 42 studies regarding the application of AI/ML methods in first-trimester screening for PE. 43 Methods: A systematic review of peer-reviewed as well as the grey literature cohort or case-control studies 44 will be conducted. Relevant information will be accessed from the following databases; PubMed, Google 45 Scholar, Web of Science, Arxiv, BioRxiv, and MedRxiv. The studies will be evaluated by two reviewers in a 46 parallel, blind assessment of the literature, a third reviewer will assess any studies in which the first two 47 reviewers did not agree. The free online tool Rayyan, will be used in this literature assessment stage. The 48 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 checklist will be used 49 to guide the review process and the methods of the studies will be assessed using the Newcastle-Ottawa 50 scale. Narrative synthesis will be conducted for all included studies. Meta-analysis will also be conducted 51 where data quality and availability allow.

52 Ethics and dissemination: The review will not require ethical approval and the findings will be published in
 53 a peer-reviewed journal using the PRISMA guidelines.

54 Keywords: Pre-Eclampsia; Artificial Intelligence; Machine Learning; Neonatal Screening; Pregnancy
 55 Trimester, First

56 Introduction

Estimated to cause 100,000 maternal deaths annually [1]; pre-eclampsia (PE) is an frequent (3-8 %) [2] and important contributor to maternal [3, 4] and perinatal [5] — mortality and morbidity. PE is also associated with cardiovascular morbidity and metabolic syndrome later in life for both mother and child [6]. Low dose aspirin treatment reduces the risk of PE, if initiated prior to week 16 [7]. It is therefore important that highrisk patients are identified early, offered preventive treatment, and then carefully monitored throughout pregnancy [5].

63 Demographic and clinical risk factors along with a plethora of first trimester biochemical and ultrasound markers of the development of PE [8-15] have been identified. These factors and markers have been 64 65 combined in several recommended algorithms [16] with variable performance [17], particularly for late-66 onset PE. There is thus a need to develop more effective screening methods [18]. An immense body of 67 knowledge has been assembled on markers and potential risk algorithms and it has been suggested that 68 future developments should rely on large-scale prospective studies [19]. However, recent improvements in 69 computing power and cloud storage will make it possible to use clinical phenotype data from patient 70 registers [20] and novel methods of data combination [21] to develop high-performance, robust, clinical 71 screening algorithms for PE [22]. Using big data in this way may also enable the definition of algorithms that 72 can identify pregnancies which will benefit from preventive treatment, as well as support research into the 73 development and implementation of individualised preventive treatments [23].

Artificial intelligence (AI) and machine learning (ML) methods may provide the key to unlocking the potential of the many markers and risk factors of PE identified to date. By enabling the combination of clinical phenotype information (extracted from electronic health records) and biomarker information along with environmental exposures, AI/ML methods provide the promise of producing a clinically relevant PE prediction algorithm [20]. Furthermore, AI/ML methods have been applied to the prediction of pregnancy complications, albeit not in a clinical care setting [24].

3

The objective of this systematic review is to identify and assess studies regarding the application of AI/ML methods in first-trimester screening for PE. The research questions (below) follow a PIO method in which the population of interest (P) are first-trimester pregnancies, the intervention (method of analysis) (I) is any AI/ML method, and the outcome (O) is prediction of PE risk.

84 Research questions

- Which AI/ML methods (I) have been used to assess PE risk (O) during the first-trimester (P)?
- How effective are these algorithms (I) at predicting PE risk (O) during the first trimester (P)?
- What risk factors have been associated with PE risk (O) during first-trimester (P) using AI/ML

88 methods (I)?

89 Methods

- 90 In accordance with the guidelines, our systematic review protocol has been submitted to the International
- 91 Prospective Register of Systematic Reviews (PROSPERO) and is, at the time of submission, awaiting
- 92 approval.

93 Study design

- 94 A systematic review of both peer-reviewed and grey literature with a meta-analysis (if possible), will be
- 95 performed in accordance with the Preferred Report Items for Systematic Reviews and Meta-analyses
- 96 (PRISMA) statement [25]. The PRISMA Protocols (PRISMA-P) checklist [26] was used to prepare this
- 97 protocol (S1 Table).

98 Eligibility criteria and information sources

- 99 We will include original studies (cohort or case-control studies) on PE, performed on samples taken during
- 100 the first trimester or performed on data which is otherwise not specific to the stage of pregnancy (e.g.
- 101 genetic variants). AI/ML methods must have been used to assess the data. Inclusion and exclusion criteria
- are listed in Table 1. Electronic searches of literature will be carried out using the following databases:
- 103 PubMed, Web of Science, Google Scholar, Arxiv, MedRxiv, and BioRxiv. No date limit will be applied to the
- searches, with the exception of the pre-print, grey literature sources (Arxiv, MedRxiv, and BioRxiv) which
- 105 will be limited to articles submitted from the 1st of January 2020 in order to reduce duplication with
- 106 published sources as well as eliminate publication failures.

107 Table 1. Inclusion/exclusion criteria.

	Inclusion	Exclusion
Population	• First trimester pregnancy	
Methods (Intervention)	 Artificial intelligence Machine learning Integrated learning Neural network Sequence learning Deep learning Network analysis Boosting gradient AdaBoost XGBoost Symbolic regression Supervised learning Unsupervised learning Random forest Decision forest Decision tree Support vector machine Reinforcement learning Bayesian network Genetic algorithm Dimensionality reduction K-nearest neighbour 	 Linear regression Logistic regression
Outcome	Pre-eclampsia	
Language	English	Non-English
Species	• Human	Animal studies
Publication Type	Original Research	 Case reports/series Reviews Commentaries Editorials Letter to editors Expert opinions Conference abstracts
Study Design	Case-controlCohort study	Meta-analysesIn vitro studies

108 Search strategy

- 109 Search terms to be used are listed in Table 2. Population terms related to the first-trimester will not be
- used as the time of testing may be unrelated to the stage of pregnancy (e.g. genetic variants, clinical
- 111 history). As an example; PubMed would be searched using the following search strategy: ("artificial
- 112 intelligence"[MeSH Terms] OR "machine learning"[MeSH Terms] OR "integrated learning"[Title/Abstract]
- 113 OR "neural network" [Title/Abstract] OR "sequence learning" [Title/Abstract] OR "deep

- 114 learning"[Title/Abstract] OR "network analysis"[Title/Abstract] OR "boosting"[Title/Abstract] OR
- 115 "AdaBoost"[Title/Abstract] OR "XGBoost"[Title/Abstract] OR "symbolic regression"[Title/Abstract] OR
- 116 "supervised learning"[Title/Abstract] OR "unsupervised learning"[Title/Abstract] OR "Random
- 117 forest"[Title/Abstract] OR "Decision forest"[Title/Abstract] OR "Decision tree"[Title/Abstract] OR "Support
- 118 vector machine"[Title/Abstract] OR "Reinforcement learning"[Title/Abstract] OR "Bayesian
- 119 network"[Title/Abstract] OR "Genetic algorithm"[Title/Abstract] OR "Dimensionality
- 120 reduction"[Title/Abstract] OR "K-nearest neighbour"[Title/Abstract] OR "K-nearest
- 121 neighbor"[Title/Abstract]) AND ("preeclampsia"[Title/Abstract] OR "pre-eclampsia"[MeSH Terms]).
- 122 Table 2. List of search terms to be applied covering the AI/ML intervention terms and PE outcome terms.

	Search Terms	
Intervention Terms	s "artificial intelligence" OR "machine learning" OR "integrated learning" OR "neural	
	network" OR "sequence learning" OR "deep learning" OR "network analysis" OR	
	"boosting" OR "AdaBoost" OR "XGBoost" OR "symbolic regression" OR "supervised	
	learning" OR "unsupervised learning" OR "Random forest" OR "Decision forest" OR	
	"Decision tree" OR "Support vector machine" OR "Reinforcement learning" OR	
	"Bayesian network" OR "Genetic algorithm" OR "Dimensionality reduction" OR "K-	
	nearest neighbour" OR "K-nearest neighbor")	
AND		
Outcome Terms	"preeclampsia" OR "pre-eclampsia"	

123 Study records

124 Data management and selection process

- 125 Literature search results will be collected and merged using Endnote (vers 20.3) and, in order to facilitate
- 126 collaboration among reviewers during the study selection process, transferred to the free online tool
- 127 Rayyan [27], where duplicates will be removed, and keyword lists based on the inclusion and exclusion
- 128 criteria will be made in order to facilitate both level 1 and 2 assessment of the literature search results.
- 129 Prior to the formal screening process, a calibration exercise will be undertaken to pilot and refine the
- 130 keyword lists. Two reviewers (PLH and MC) will independently assess titles and abstracts against the
- 131 inclusion and exclusion criteria, as guided by the keyword lists, in order to identify eligible articles. Articles
- 132 will be rated as 'included', 'excluded' or 'maybe' (i.e. insufficient information in abstract to decide
- eligibility) and a full-text review will then be performed by both reviewers for all 'included' and 'maybe'

- 134 articles. Any discrepancies between the first and second reviewer will be discussed and in the event that a
- 135 consensus cannot be reached a third reviewer (CMH or CW) will make the final decision regarding eligibility.
- 136 A PRISMA flow diagram will be drawn to demonstrate the stages of the literature selection process and
- 137 record the reason for excluding studies (Fig 1) [25].
- **Fig 1. PRISMA Flow diagram.** An illustration of the process of selecting studies for review.

139 Critical Appraisal of selected studies

The reviewers (PLH and MC) will assess the quality of all eligible studies using the Newcastle-Ottawa Quality Assessment Scale (NOS) for case-control and cohort studies [28]. NOS is a validated quality assessment tool which is divided into three sections focused on selection of participants, comparability of study groups, and ascertainment of outcomes. Each section contains a number of criteria for which a study can be awarded a star, the maximum number of stars that can be awarded is nine. Any discrepancy in NOS scoring will be settled by a third reviewer (CMH or CW). If a discrepancy persists then the average score will be used. Studies with 7-9 stars will be considered high-quality and their data used in a meta-analysis.

147 Data collection

148 One reviewer (PLH) will extract data from the included studies using an excel spreadsheet. Data from 149 multiple reports pertaining to the same study will be linked so as not to report duplicate results. The excel 150 spreadsheet will collect data on the first author, publication year, study period, country of study, type of 151 study, peer-reviewed status, pre-publication status, sample size, maternal age, gestational age at sampling, 152 blood pressure measurements, maternal body mass index, birth weight, risk markers, AI/ML method, all 153 reported outcomes pertaining to PE, and NOS scores. The excel sheet will be adapted following a pilot test 154 on 10 articles, selected to represent various AI/ML methods and risk factors, in order to ensure all relevant 155 data is extracted. The second reviewer (MC) will approve the excel sheet and check the accuracy of the 156 data.

157 Data synthesis

- 158 Tables will be created to summarise the characteristics of the included studies. A narrative analysis will be
- 159 presented with reference to the particular AI/ML method and type of data used in the study. We intend to
- 160 compare the diagnostic efficiency of the different methods, if sufficient studies will be found. If possible,
- 161 considering the wide range of possible AI/ML methods employed, a meta-analysis will be performed using
- 162 R package meta. In the event that a meta-analysis cannot be performed, data for similar AI/ML methods
- 163 will be compiled and reported together. Strength of evidence will be graded by two reviewers (PLH and
- 164 MC) using the Evidence-based Practice Centre 2015 guidelines [29].

¹⁶⁵ Patient and public involvement

166 Patients or the public will not be involved in this systematic review.

167 Ethics and dissemination

- 168 This systematic review will not need ethical approval because it will retrieve and synthesise data from
- 169 publically available published and pre-published studies. Study results will be disseminated through
- 170 scientific publications presented at relevant local and international scientific conferences.

171 Discussion

172 Studies have been performed which use AI/ML methods to predict complications in pregnancy [24].

173 However, as most studies focus on second trimester pregnancies an overview of first trimester pregnancy

174 PE prediction using AI/ML methods is needed as identification of PE risk in the first trimester can be used to

- select pregnancies that may benefit from preventive treatment with Low dose aspirin, which has been
- 176 documented to reduce the occurrence of PE [7, 30].

Many AI/ML methods are currently in use within research and development [21]; this review would allow us to comment on the ability of these methods to support patient participation in decisions with reference to the "explainability" or "interpretability" of the result. These two concepts refer to the ability to explain how the algorithm parameters relates to the result (explainability of black-box models) and how understandable and trustworthy the algorithm results are (interpretability of white-box models) [31]. As risk assessment for PE supports high-risk decisions it is a very important that patients and doctors can understand which underlying factors determine the outcome.

184 This systematic review will establish the current state of knowledge concerning the prediction of PE during 185 the first trimester through use of AI/ML methods and will provide the highest level of evidence to inform 186 future research as well as the development of first-trimester, PE screening algorithms. However, the 187 considerable heterogeneity expected among the included literature (i.e. different AI/ML methods used, 188 different sample type or gestational ages at time of sampling) may pose a challenge for consistent and 189 comprehensive data extraction. Consequently, meta-analysis will be limited by the quality and quantity of 190 data available. Any significant amendments to this systematic review protocol will require the approval of 191 all authors and will be documented, with the date of the amendment and the rationale for the amendment, on the PROSPERO record, updated protocol document, and in the final manuscript. The review findings will 192 193 be published in a peer-reviewed open-access scientific journal at the conclusion of this study.

194 References

1951.Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-196eclampsia. Lancet. 2016;387(10022):999-1011. Epub 2015/09/08. doi: 10.1016/S0140-6736(15)00070-7.197PubMed PMID: 26342729.

1982.Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia199and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1-7. Epub 2013/06/12.200doi: 10.1016/j.ejogrb.2013.05.005. PubMed PMID: 23746796.

Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, et al. Global causes of maternal
 death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323-33. Epub 2014/08/12. doi:
 10.1016/S2214-109X(14)70227-X. PubMed PMID: 25103301.

Zhang J, Meikle S, Trumble A. Severe maternal morbidity associated with hypertensive
 disorders in pregnancy in the United States. Hypertens Pregnancy. 2003;22(2):203-12. Epub 2003/08/12.
 doi: 10.1081/PRG-120021066. PubMed PMID: 12909005.

von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton Pipkin F, Cote AM, et al. Prediction
 of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model.
 Lancet. 2011;377(9761):219-27. Epub 2010/12/28. doi: 10.1016/S0140-6736(10)61351-7. PubMed PMID:
 21185591.

2116.Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia. Lancet. 2021;398(10297):341-54.212Epub 2021/05/31. doi: 10.1016/S0140-6736(20)32335-7. PubMed PMID: 34051884.

Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin
 versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017;377(7):613-22.
 Epub 20170628. doi: 10.1056/NEJMoa1704559. PubMed PMID: 28657417.

2168.Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH. Maternal serum placental growth217factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol.2182008;32(6):732-9. Epub 2008/10/29. doi: 10.1002/uog.6244. PubMed PMID: 18956425.

Christiansen M, Hedley PL, Placing S, Wojdemann KR, Carlsen AL, Jorgensen JM, et al.
 Maternal Serum Resistin Is Reduced in First Trimester Preeclampsia Pregnancies and Is a Marker of Clinical
 Severity. Hypertension in Pregnancy. 2015;34(4):422-33. doi: 10.3109/10641955.2014.913615. PubMed
 PMID: WOS:000366271200003.

10. Cnossen JS, Morris RK, ter Riet G, Mol BW, van der Post JA, Coomarasamy A, et al. Use of
uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a
systematic review and bivariable meta-analysis. CMAJ. 2008;178(6):701-11. Epub 2008/03/12. doi:
10.1503/cmaj.070430. PubMed PMID: 18332385; PubMed Central PMCID: PMCPMC2263112.

Grill S, Rusterholz C, Zanetti-Dallenbach R, Tercanli S, Holzgreve W, Hahn S, et al. Potential
markers of preeclampsia--a review. Reproductive biology and endocrinology : RB&E. 2009;7:70. Epub
2009/07/16. doi: 10.1186/1477-7827-7-70. PubMed PMID: 19602262; PubMed Central PMCID:
PMCPMC2717076.

Hedley PL, Placing S, Wojdemann K, Carlsen AL, Shalmi AC, Sundberg K, et al. Free leptin
 index and PAPP-A: a first trimester maternal serum screening test for pre-eclampsia. Prenat Diagn.
 2010;30(2):103-9. Epub 2009/12/17. doi: 10.1002/pd.2337. PubMed PMID: 20013873.

23413.Laigaard J, Sorensen T, Placing S, Holck P, Frohlich C, Wojdemann KR, et al. Reduction of the235disintegrin and metalloprotease ADAM12 in preeclampsia. Obstet Gynecol. 2005;106(1):144-9. Epub2362005/07/05. doi: 10.1097/01.AOG.0000165829.65319.65. PubMed PMID: 15994630.

23714.Spencer K, Cowans NJ, Nicolaides KH. Low levels of maternal serum PAPP-A in the first238trimester and the risk of pre-eclampsia. Prenat Diagn. 2008;28(1):7-10. Epub 2007/11/15. doi:

239 10.1002/pd.1890. PubMed PMID: 18000943.

24015.De Villiers CP, Hedley PL, Placing S, Wojdemann KR, Shalmi AC, Carlsen AL, et al. Placental241protein-13 (PP13) in combination with PAPP-A and free leptin index (fLI) in first trimester maternal serum

screening for severe and early preeclampsia. Clin Chem Lab Med. 2017;56(1):65-74. Epub 2017/07/14. doi:
10.1515/cclm-2017-0356. PubMed PMID: 28704180.

O'Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, de Alvarado M, et al. Multicenter
screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison
with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol. 2017;49(6):756-60. doi:
10.1002/uog.17455. PubMed PMID: 28295782.

Tan MY, Syngelaki A, Poon LC, Rolnik DL, O'Gorman N, Delgado JL, et al. Screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. Ultrasound Obstet Gynecol.
2018;52(2):186-95. Epub 2018/06/14. doi: 10.1002/uog.19112. PubMed PMID: 29896812.

18. Chaemsaithong P, Sahota DS, Poon LC. First trimester preeclampsia screening and prediction.
Am J Obstet Gynecol. 2022;226(2S):S1071-S97 e2. Epub 20200716. doi: 10.1016/j.ajog.2020.07.020.
PubMed PMID: 32682859.

25419.Townsend R, Khalil A, Premakumar Y, Allotey J, Snell KIE, Chan C, et al. Prediction of pre-255eclampsia: review of reviews. Ultrasound Obstet Gynecol. 2019;54(1):16-27. doi: 10.1002/uog.20117.256PubMed PMID: 30267475.

 257
 20.
 Myatt L. The prediction of preeclampsia: the way forward. Am J Obstet Gynecol.

 258
 2022;226(2S):S1102-S7 e8. Epub 20210327. doi: 10.1016/j.ajog.2020.10.047. PubMed PMID: 33785181.

25921.Christiansen M, Wilstrup C, Hedley PL. Explainable "White-box" machine learning is the way260forward in pre-eclampsia screening. Am J Obstet Gynecol. 2022. Epub 20220629. doi:26140.4016 (incide 2022) 06.057. Pub Maid DNUD: 25770500

261 10.1016/j.ajog.2022.06.057. PubMed PMID: 35779588.

Topol EJ. High-performance medicine: the convergence of human and artificial intelligence.
 Nat Med. 2019;25(1):44-56. Epub 20190107. doi: 10.1038/s41591-018-0300-7. PubMed PMID: 30617339.
 Bica I, Alaa AM, Lambert C, van der Schaar M. From Real-World Patient Data to Individualized
 Treatment Effects Using Machine Learning: Current and Future Methods to Address Underlying Challenges.

Clin Pharmacol Ther. 2021;109(1):87-100. Epub 20200628. doi: 10.1002/cpt.1907. PubMed PMID:
32449163.

Bertini A, Salas R, Chabert S, Sobrevia L, Pardo F. Using Machine Learning to Predict
 Complications in Pregnancy: A Systematic Review. Front Bioeng Biotechnol. 2021;9:780389. Epub
 20220119. doi: 10.3389/fbioe.2021.780389. PubMed PMID: 35127665; PubMed Central PMCID:
 PMCPMC8807522.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA
2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Epub
2021/03/31. doi: 10.1136/bmj.n71. PubMed PMID: 33782057; PubMed Central PMCID: PMCPMC8005924.
26. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting

items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
Epub 20150101. doi: 10.1186/2046-4053-4-1. PubMed PMID: 25554246; PubMed Central PMCID:
PMCPMC4320440.

279 27. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for
280 systematic reviews. Syst Rev. 2016;5(1):210. Epub 2016/12/07. doi: 10.1186/s13643-016-0384-4. PubMed
281 PMID: 27919275; PubMed Central PMCID: PMCPMC5139140.

28228.Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa283Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses Ottawa, Canada: Ottawa284Hospital Research Institute; 2019 [cited 2020 20/01/2020]. Available from:

285 <u>http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</u>.

28629.Berkman ND, Lohr KN, Ansari MT, Balk EM, Kane R, McDonagh M, et al. Grading the strength287of a body of evidence when assessing health care interventions: an EPC update. J Clin Epidemiol.

288 2015;68(11):1312-24. Epub 20141220. doi: 10.1016/j.jclinepi.2014.11.023. PubMed PMID: 25721570.

28930.ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy. Obstet Gynecol.2902018;132(1):e44-e52. doi: 10.1097/AOG.0000000002708. PubMed PMID: 29939940.

29131.Barragan-Montero A, Bibal A, Dastarac MH, Draguet C, Valdes G, Nguyen D, et al. Towards a292safe and efficient clinical implementation of machine learning in radiation oncology by exploring model293interpretability, explainability and data-model dependency. Phys Med Biol. 2022;67(11). Epub 20220527.

294 doi: 10.1088/1361-6560/ac678a. PubMed PMID: 35421855.

295 Supporting information

296 S1 Table. PRISMA-P 2015 checklist

297 Statements

298 **Funding:** The author(s) received no specific funding for this work.

299 Author contributions: MC is the guarantor. PLH and MC drafted the manuscript and contributed to the

300 development of the selection criteria, the critical appraisal strategy and data extraction criteria. PLH

- 301 developed the search strategy. CW and CMH provided statistical expertise. CW provided expertise on
- 302 artificial intelligence and machine learning. All authors read, provided feedback and approved the final
- 303 manuscript.
- 304 **Competing interests:** The authors have declared that no competing interests exist.
- 305 Abbreviations: AI, artificial intelligence; ML, machine learning; NOS, Newcastle-Ottawa Quality Assessment
- 306 Scale; **PE**, pre-eclampsia; **PRISMA**, preferred reporting items for systematic reviews and meta-analyses;
- 307 **PRISMA-P**, PRISMA-protocols; **PROSPERO**, the international prospective register of systematic reviews.



Figure